Mar 3 2010
Cyntellect,
Inc., a privately-held life sciences company commercializing
products to advance the study of cell biology, stem cell research,
biopharmaceutical production, and drug discovery, has entered into an
agreement with Harvard University and the Howard Hughes Medical
Institute to provide their researchers with the LEAP™
Cell Processing Workstation. The LEAP Workstation is an
award-winning, microplate-based cytometry system used for in situ
cell analysis, purification, and processing that will give these
researchers the ability to conduct research across a broad spectrum of
stem cell related projects. The LEAP Workstation allows rapid and
automated physical passaging of stem cells and consistent embryoid body
generation, in addition to unique in situ cell purification
protocols.
“We are thrilled to participate in this relationship with Harvard and
HHMI, and to help fuel the truly innovative stem cell research
undertaken by their scientists”
Harvard researchers, including Amy Wagers, Associate Professor of Stem
Cell and Regenerative Biology and Howard Hughes Medical Institute (HHMI)
Early Career Scientist, will work with Cyntellect’s Stem Cell Manager on
the LEAP Workstation. Initial projects will use the LEAP Workstation to
selectively process stem cells to define the factors and mechanisms that
regulate the migration, expansion, and regenerative potential of adult
blood-forming (hematopoietic) and muscle-forming (myogenic) stem cells.
Blood-forming stem cells generate all of the red and white blood cells
needed to deliver oxygen to body tissues, fight infection, and stop
bleeding. Similarly, muscle-forming stem cells generate mature muscle
fibers necessary for controlled contraction of skeletal muscle.
“We are thrilled to participate in this relationship with Harvard and
HHMI, and to help fuel the truly innovative stem cell research
undertaken by their scientists,” said Dr. Fred Koller, Cyntellect’s
Chief Technology Officer. “Stem cell research has the potential to
significantly improve drug discovery processes and revolutionize new
therapeutics. The ability to control differentiation of stem cells into
specialized cell types with high yield and precision is a key success
factor that will determine the ultimate utility of such research.”
Harvard’s stem cell research community, including scientists in its
Faculty of Arts and Sciences, the Harvard Medical School, and in
affiliated hospitals and research institutions, is the largest direct
collaboration of stem cell researchers in the world.